MK-1167 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medicine, MK-1167, which might alleviate symptoms of Alzheimer's disease, a condition affecting memory and daily activities. Researchers aim to observe how this medicine behaves in the body and confirm its safety for use. The trial will compare two different forms of MK-1167 to evaluate their effects. Participants should be healthy, have a body mass index (BMI) between 18 and 32, and not have major health issues or a recent history of smoking. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators for specific guidance.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that MK-1167 is under study to assess its safety and tolerability. In earlier studies, researchers examined MK-1167 in individuals with Alzheimer's disease to understand its effects and safety. Although detailed information on side effects from those studies is not provided here, ongoing research helps determine safe doses.
This study is in its early stages, with researchers still evaluating its safety in healthy individuals. This phase is crucial for assessing tolerability and identifying any side effects.
Both versions of MK-1167, Form 1 and Form 2, are being tested to gather more information about their safety. The treatment remains experimental, and complete safety data is not yet available. However, this trial is a vital step in ensuring the treatment's safety for future use in individuals with Alzheimer's disease.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MK-1167 because it represents a new approach to treatment by offering a different form of delivery. Unlike current treatments that may require intravenous administration or more complex dosing regimens, MK-1167 is taken orally, which can make it more convenient for patients. Additionally, MK-1167 may feature a novel mechanism of action, setting it apart from existing standard therapies. This could potentially lead to improved outcomes and a new option for patients seeking effective treatment.
What evidence suggests that this trial's treatments could be effective for Alzheimer's disease?
Research has shown that MK-1167 might improve memory and thinking skills in people with Alzheimer's disease. Earlier studies found that this treatment can enhance the effectiveness of other Alzheimer's treatments, possibly providing more relief. Researchers have also studied MK-1167 for its effect on glutamate, a brain chemical important for learning and memory. Although more research is needed, these findings offer hope that MK-1167 could be a helpful treatment for Alzheimer's disease. In this trial, participants will receive either MK-1167 Form 1 or MK-1167 Form 2 to further evaluate its effects.12345
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for healthy individuals with a BMI between 18 and 32. Participants should be in good health without any major medical conditions.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive single doses of two formulations of MK-1167 to evaluate pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MK-1167
Trial Overview
The study is testing different forms of MK-1167, a new medication intended to treat Alzheimer's disease symptoms. It aims to understand how the drug behaves in the body over time and assess its safety and tolerability.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants receive MK-1167 Form 1 orally.
Participants receive MK-1167 Form 2 orally.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
Merck Showcases Data for Alzheimer's Disease ...
The trial assessed the effect of single doses of MK-1167 on glutamate metabolism in the prefrontal cortex of healthy adult male volunteers, as ...
NCT06285240 | Efficacy and Safety of MK-1167 in ...
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable ...
A Study to Evaluate the Efficacy and Safety of MK-1167 in ...
The clinical trial is evaluating the safety of an investigational drug, MK-1167, and how well it may work when people take it with their current Alzheimer's ...
Mk-1167 – Application in Therapy and Current Clinical ...
Improve memory and thinking skills in people with Alzheimer's disease. · Enhance the effectiveness of existing Alzheimer's treatments when used in combination.
Merck Showcases Data for Alzheimer's Disease ...
The trial assessed the effect of single doses of MK-1167 on glutamate metabolism in the prefrontal cortex of healthy adult male volunteers, as ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.